NASDAQ:XOMAXOMA Stock Price, Forecast & News

XOMA's stock was trading at $19.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, XOMA shares have decreased by 2.2% and is now trading at $19.08. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for XOMA.

XOMA is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for XOMA.

XOMA Corp (NASDAQ:XOMA) issued its earnings results on Tuesday, May, 5th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $0.33. The biotechnology company had revenue of $0.80 million for the quarter, compared to analyst estimates of $3.40 million. XOMA had a negative return on equity of 34.27% and a negative net margin of 102.32%. View XOMA's earnings history.

2 brokerages have issued 1-year target prices for XOMA's shares. Their forecasts range from $29.00 to $30.00. On average, they expect XOMA's stock price to reach $29.50 in the next twelve months. This suggests a possible upside of 54.6% from the stock's current price. View analysts' price targets for XOMA.

Press coverage about XOMA stock has been trending neutral on Sunday, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. XOMA earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about XOMA.

Some companies that are related to XOMA include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other XOMA investors own include Cytokinetics (CYTK), Alnylam Pharmaceuticals (ALNY), Ascent Solar Technologies (ASTI), CTI BioPharma (CTIC), TransEnterix (TRXC), Opko Health (OPK), Gilead Sciences (GILD), Uranium Energy (UEC), Ekso Bionics (EKSO) and NXP Semiconductors (NXPI).

XOMA trades on the NASDAQ under the ticker symbol "XOMA."

Shares of XOMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of XOMA stock can currently be purchased for approximately $19.08.

XOMA has a market capitalization of $210.26 million and generates $18.37 million in revenue each year. The biotechnology company earns $-1,980,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis. XOMA employs 11 workers across the globe.

The official website for XOMA is www.xoma.com.

XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-204-7200 or via email at [email protected]